NRx Pharmaceuticals (NRXP) Company Overview

• Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New York February 10 th-12th WILMINGTON, Del. , Feb. 6, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE"), a medical and technology driven company and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. announced today that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals will be presenting a Company update at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11 th-12th.

This financing is expected to support filing of New Drug Applications for NRX-100 (ketamine) and NRX-101, and to support launch of HOPE Therapeutics Investment consists of $3.5 million in above the market equity and $5.4 million in Senior Secured Notes; expected to fund current operations into 2026 WILMINGTON, Del. , Jan. 28, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", "NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has entered into a binding agreement for a registered direct offering of its common stock with expected gross proceeds of $3.5 million (the "Financing") with certain institutional investors.

Company received written notice from the Nasdaq Listing Qualifications Staff stating that the Company regained compliance with the applicable Nasdaq minimum market value of listed securities continued listing requirement Nasdaq stated that the matter is now closed WILMINGTON, Del. , Jan. 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that on January 17, 2025, it received written notice from the Nasdaq Listing Qualifications Staff (the "Staff") stating that the Company regained compliance with the market value of listed Securities ("MVLS") requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the "Rule") for continued listing on the Nasdaq Capital Market, and the matter is now closed.

WILMINGTON, Del. , Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., a development stage medical and technology driven company and wholly owned subsidiary of NRx, today announced the appointment of Mr.

"'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay Gupta David Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry field Kadima Neuropsychiatry Institute identified as planned HOPE Flagship Clinic pending acquisition closing Dr. Feifel is expected to join HOPE as Chief Medical Innovation Officer MIAMI , Jan. 14, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today alerted investors that Kadima Neuropsychiatry Institute's Founder David Feifel, MD PHD was featured as an expert in a program on ketamine entitled "'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay Gupta. HOPE previously announced that Kadima is identified as the Company's planned flagship clinic acquisition, upon closing of the transaction.

Management believes uplisting has the potential to provide shareholders with improved liquidity Requires NRx Pharmaceuticals to meet certain listing requirements Company has advised NASDAQ that current shares outstanding is 15.7 million WILMINGTON, Del. , Jan. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced it has applied to NASDAQ to uplist the Company's securities to the NASDAQ Global Market (NASDAQ GM).

The Keynote Address, entitled " Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD ," will be presented at 10:30AM PT on Sunday January 12th, 2025 Prof. David Feifel MD PHD, designated Chief Medical Innovation Officer of HOPE and Founder of the Kadima Neuropsychiatry Institute, is an international thought leader in the interventional psychiatry space NRx Pharmaceuticals recently initiated filing of its NDA for NRX-100 (IV ketamine) for the treatment of suicidal depression Recent announcement of Kadima Neuropsychiatry Institute and Dura Medical as planned cornerstone acquisitions for HOPE Therapeutic's international network of interventional psychiatry clinics $27 Million in anticipated funding for HOPE Clinic acquisitions and pharmaceutical operations under a binding Term Sheet with an Institutional Investor MIAMI , Jan. 7, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced that Jonathan Javitt MD MPH, Founder and CEO of NRx and Co-CEO of HOPE, and Prof.

NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.

Anticipated c apital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical operations. Purchase of $25 m illion in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions.